Corcept Therapeutics (CORT) Tops Q4 EPS by 3c

Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.18, $0.03 better than the analyst estimate of $0.15. Revenue for the quarter came in at $66.8 million versus the consensus estimate of $69.61 million.

GUIDANCE:

Corcept Therapeutics sees FY2019 revenue of $285-315 million, versus the consensus of $298.3 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• S&P 500 may pull back before midterms, but Citi says buy the dip